Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in share interests.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific executive transaction rather than a financial performance report.
Material Changes
The material change disclosed is the vesting of 8,897.219 ordinary shares for Dr. P. Vallance under the GlaxoSmithKline Deferred Investment Award on January 29, 2011. Following this vesting, Dr. Vallance received a payment of £11.51 per ordinary share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(b).
Key Facts for Investors
- Executive Transaction: Dr. P. Vallance vested 8,897.219 ordinary shares on January 29, 2011.
- Payment Details: The vesting resulted in a payment of £11.51 per share.
- Notification Date: The company was advised of the transaction on February 1, 2011.
- Financial Data: No financial performance metrics are included in this specific filing.